Skip to main content
. 2021 Sep 22;394(12):2363–2379. doi: 10.1007/s00210-021-02149-4

Fig. 6.

Fig. 6

Effects of runcaciguat on urinary and plasma biomarkers in L-NAME-supplemented RenTG rats treated with either vehicle or runcaciguat (0.3, 1, or 3 mg/kg/bid) at study end (8 weeks of treatment). Urinary levels of A NGAL, B OPN, and C KIM-1 and plasma levels of D NGAL and E OPN. Data are mean ± SEM; N = 8–13 per group after completion of the study. Significant changes were determined by one-way ANOVA followed by Dunnett’s multiple comparison with * for P < 0.05